Dr. Lindskog dismisses the potential riskiness of switching from a traditional seed train based on increasingly voluminous reactors to high-density perfusion reactors.
"The regulatory challenges have been how to define a batch, how to handle contamination, and validating the manufacturing process ,""she explains. ``"